All In Biotech

Drug Trial Radar · NCT05433272

Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated

A Randomized, Double-Blind, Active-controlled Phase Ⅲ Clinical Trial to Evaluate the Immunogenicity and Safety of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated in Healthy People in Colombia

Last checked: Nov 20, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,400

Planned (sponsor's estimate)

Start

Aug 10, 2023

Primary completion

Sep 10, 2023

Study completion Sep 10, 2023

Sponsor

Sponsor type
Industry
Collaborators
Sinovac Life Sciences Co., Ltd.
First posted
Jun 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 3 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, active-controlled phase Ⅲ clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of one booster dose of trivalent COVID-19 vaccine (vero cell), inactivated, prototype strain, delta strain and omicron strain in healthy people aged 3 years old and above and have completed two or three doses of CoronaVac® in Colombia.

Conditions

  • COVID-19

Interventions

  • Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron StrainBiological

    The Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain was developed by Sinovac Life Science Ltd. The antigen content of trivalent COVID-19 vaccine is a total of 18μg/0.5 ml, including 1200 SU/6 µg/0.5 ml for Prototype strain, 1200 SDU/6 µg/0.5 ml for Delta strain, and 1200 SOU/6 µg/0.5 ml for Omicron strain. The routine of administration is Intramuscular injection into deltoid region.

  • COVID-19 Vaccine (Vero Cell), InactivatedBiological

    The COVID-19 Vaccine (Vero Cell),Inactivated was manufactured by Sinovac Life Science Ltd.The antigen content of the active-controlled vaccine (CoronaVac) is 600 SU/3 µg/0.5 ml.The routine of administration is Intramuscular injection into deltoid region.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titer (GMT) of the neutralizing antibody to SARS-CoV-2 Delta strain and Omicron strainTime frame: At 14 days after one booster dose
  2. Seroconversion rate of the neutralizing antibody to SARS-CoV-2 Delta strain and Omicron strainTime frame: At 14 days after one booster dose
  3. GMT of the neutralizing antibody to SARS-CoV-2 Prototype strainTime frame: At 14 days after one booster dose
  4. Seroconversion rate of the neutralizing antibody to SARS-CoV-2 Prototype strainTime frame: At 14 days after one booster dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinica de la Costa

    Barranquilla, Colombia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.